NO20070061L - 3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav - Google Patents

3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav

Info

Publication number
NO20070061L
NO20070061L NO20070061A NO20070061A NO20070061L NO 20070061 L NO20070061 L NO 20070061L NO 20070061 A NO20070061 A NO 20070061A NO 20070061 A NO20070061 A NO 20070061A NO 20070061 L NO20070061 L NO 20070061L
Authority
NO
Norway
Prior art keywords
ribofuranosylthiazolo
beta
compounds
nucleosides
pyridimine
Prior art date
Application number
NO20070061A
Other languages
English (en)
Norwegian (no)
Inventor
David Louis Clark
Stephen E Webber
Devron R Averett
Erik J Rueden
Joseph R Lennox
Alan X Xiang
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34959084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20070061(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Publication of NO20070061L publication Critical patent/NO20070061L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO20070061A 2004-06-07 2007-01-04 3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav NO20070061L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/018011 WO2005121162A1 (fr) 2004-06-07 2004-06-07 Nucleosides 3-?-d-ribofuranosylthiazolo[4,5-d]pyridimine et leurs utilisations

Publications (1)

Publication Number Publication Date
NO20070061L true NO20070061L (no) 2007-03-05

Family

ID=34959084

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070061A NO20070061L (no) 2004-06-07 2007-01-04 3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav

Country Status (21)

Country Link
US (1) US20080070852A1 (fr)
EP (1) EP1758916B1 (fr)
JP (1) JP4856638B2 (fr)
CN (1) CN1964985A (fr)
AR (1) AR049203A1 (fr)
AU (1) AU2004320625B2 (fr)
BR (1) BRPI0418887A (fr)
CA (1) CA2566541C (fr)
ES (1) ES2399891T3 (fr)
IL (1) IL179529A0 (fr)
IS (1) IS8575A (fr)
MX (1) MXPA06014182A (fr)
NO (1) NO20070061L (fr)
PA (1) PA8635901A1 (fr)
PE (1) PE20060455A1 (fr)
RU (1) RU2006146204A (fr)
SV (1) SV2006002135A (fr)
TN (1) TNSN06403A1 (fr)
TW (1) TW200612969A (fr)
UY (1) UY28943A1 (fr)
WO (1) WO2005121162A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009486D0 (en) 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
US7560544B2 (en) * 2004-12-17 2009-07-14 Anadys Pharmaceuticals, Inc. 3,5-Disubsitituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
EP2007789B1 (fr) 2006-04-11 2015-05-20 Novartis AG Inhibiteurs spirocycliques du VIH/du virus de l'hépatite C
GB0609178D0 (en) 2006-05-09 2006-06-21 Univ Cardiff Novel compounds
CL2007001427A1 (es) * 2006-05-22 2008-05-16 Novartis Ag Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
BRPI0717741A2 (pt) * 2006-10-17 2014-04-08 Anadys Pharmaceuticals Inc Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
DK2014771T3 (en) * 2007-06-25 2015-03-09 Anadys Pharmaceuticals Inc Continuous process for the enzymatic hydrolysis
EP2019113A1 (fr) * 2007-07-26 2009-01-28 Anadys Pharmaceuticals, Inc. Nouveaux sels cristallins de 5-amino-3-(2',3'-di-o-acétyl-bêta-d-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
MX2012003126A (es) * 2009-09-21 2012-06-19 Gilead Sciences Inc Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos.
JP5909495B2 (ja) 2010-10-08 2016-04-26 ノバルティス アーゲー スルファミドｎｓ３阻害剤のビタミンｅ製剤
CN102153548B (zh) * 2011-02-24 2012-11-28 河北大学 一种含有噻唑（嗪）烷酮环的类核苷衍生物及其制备方法和其在药物制剂中的应用
TW202317144A (zh) 2021-06-14 2023-05-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物
WO2023196458A1 (fr) * 2022-04-06 2023-10-12 VenatoRx Pharmaceuticals, Inc. Analogues nucléosidiques biodisponibles par voie orale
CN116589606B (zh) * 2022-12-01 2024-05-28 中国药科大学 一种丁酰化酵母葡聚糖及其制备方法、应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041426A (en) * 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
US4880784A (en) * 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
AP2004003069A0 (en) * 2001-11-27 2004-06-30 Anadys Pharmaceuticals Inc 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.

Also Published As

Publication number Publication date
SV2006002135A (es) 2006-05-08
BRPI0418887A (pt) 2007-10-30
WO2005121162A1 (fr) 2005-12-22
EP1758916A1 (fr) 2007-03-07
ES2399891T3 (es) 2013-04-04
AR049203A1 (es) 2006-07-05
US20080070852A1 (en) 2008-03-20
CN1964985A (zh) 2007-05-16
CA2566541A1 (fr) 2005-12-22
CA2566541C (fr) 2012-10-09
MXPA06014182A (es) 2007-06-25
AU2004320625B2 (en) 2009-08-27
RU2006146204A (ru) 2008-07-20
IS8575A (is) 2006-12-05
EP1758916B1 (fr) 2012-11-21
TW200612969A (en) 2006-05-01
JP4856638B2 (ja) 2012-01-18
IL179529A0 (en) 2007-05-15
UY28943A1 (es) 2006-01-31
TNSN06403A1 (en) 2008-02-22
AU2004320625A1 (en) 2005-12-22
JP2008501792A (ja) 2008-01-24
PE20060455A1 (es) 2006-06-19
PA8635901A1 (es) 2006-07-03

Similar Documents

Publication Publication Date Title
TNSN07208A1 (en) 3,5-DISUBTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d] PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
YU45204A (sh) 3-BETA-D-RIBOFURANOZILTIAZOLO/4,5-d/ PIRIMIDINSKI NUKLEOZIDII NJIHOVA UPOTREBA
NO20070061L (no) 3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav
WO2006113864A3 (fr) Composes d'oxindole et leurs utilisations comme agents therapeutiques
NO20072548L (no) Xantinderivater med HM74A reseptoraktivitet
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
WO2006004741A3 (fr) 3-aminocyclopentanecarboxamides utilises en tant que modulateurs des recepteurs des chimiokines
NO20063787L (no) Terapeutiske preparater
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
TW200611695A (en) Pyrrolopyridine derivatives
WO2002079169A8 (fr) Composes de dihydropyrimidine cyano-substitues et leur utilisation pour traiter des maladies
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
WO2002079149A3 (fr) Nouveaux composes de dihydropyrimidine cyano substituee et leur utilisation therateutique
AU2003260436A1 (en) Pyrimidine compounds
NO20064974L (no) terapeutiske midler
ATE451350T1 (de) Arylalkylsulfonamide als therapeutische mittel zur behandlung von knochenleiden
UA91697C2 (en) 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
ATE472323T1 (de) Behandlung von statin-nebenwirkungen mit uridinderivaten
DOP2005000261A (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4,5-d] pirrimidin-2-ona 3,5-disustituida y 3,5,7-trisustituida y profarmacos de los mismo
UA83142C2 (en) 3-aminocyclopentane carboxyamidine as modulators of chemokine receptors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application